Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-098774
Filing Date
2025-07-25
Accepted
2025-07-25 16:05:06
Documents
1
Period of Report
2025-07-23

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3320
  Complete submission text file 0000950170-25-098774.txt   4796
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT STE 200 SAN DIEGO CA 92121
Business Address
Dulac Edward J III (Reporting) CIK: 0001821530 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37766 | Film No.: 251151693